Our Mission
We are developing innovative drugs to target challenging protein-protein interactions in cancer, leveraging our proprietary phenotypic drug discovery platform. Having successfully completed hit validation for our first program, we are now seeking seed investors to advance to the lead identification stage.
Seed Round Open
A €2.5M seed round is now open. We are advancing our first-in-class STAT5 inhibitor program to lead nomination — backed by Austrian public co-financing that makes every invested euro work two to three times harder. If early-stage oncology is in your scope, let’s talk. Read more about this opportunity here.
Our STAT5 Program
More than 60% of AML patients on targeted therapies develop resistance — and for most, it is fatal. RIANA’s STAT5 inhibitor targets the convergent driver of that resistance with a first-in-class small-molecule approach. Read more about our program, roadmap and market opportunity here.
Our Science
We are pioneering a first-in-class strategy to selectively disable oncogenic STAT5 signaling at its source. In hematologic malignancies such as acute myeloid leukemia (AML), pathological STAT5 activity is driven by oligomerization — a mechanism distinct from its essential physiological dimerization in healthy cells. By specifically targeting STAT5 oligomerization with small molecules, we aim to shut down malignant signaling while preserving normal cellular function.
This precision-based approach has the potential to redefine how STAT5-driven cancers are treated — delivering highly effective therapies with reduced side effects and expanding the boundaries of what is considered druggable.
Read more about our science.
Our Team
RIANA Therapeutics is a female-led biotechnology company with a small focused core team combining expertise in molecular oncology, STAT5 biology, and small-molecule drug discovery. RIANA is led by co-founder and CEO Anna Orlova, and co-founder and CBO Christine Ruckenbauer.
RIANA is supported by a distinguished Scientific Advisory Board with deep expertise in STAT5 biology, medicinal chemistry, and oncology drug development, as well as strategic and financial guidance.
Klick here to learn more about our team.
RIANA NEWS
Seed Round Open
Seed round:€2.5m total50% equity50% grants >€100K tickets Q4/26 closing RIANA Therapeutics is currently raising a €2.5M seed round to advance our STAT5 inhibitor program to lead nomination. Having successfully secured Austrian non-dilutive public funding four times, we offer investors an unusually capital-efficient entry point: with co-financing rates of up to 60% at this stage, every…
Keep reading
Austrian Start-up Award PHÖNIX 2026 Finalist
RIANA Therapeutics has been nominated as a finalist in the Spin-off category of the Austrian Gründungspreis PHÖNIX 2026! Initiatives like PHÖNIX help make visible how research can translate into real-world impact, something essential for the development of the biotech ecosystem in Austria. The winners will be announced in Vienna on 12 March. Link to Phönix…
Keep reading
Happy 3rd Birthday, RIANA!
Time is rushing – especially in a buzzing and vibrant field like biotech. Three years ago, RIANA Therapeutics started with a bold scientific vision and the belief that small, focused teams can tackle big challenges. Today, we are proud of how far we’ve come — from early scientific validation to advancing our STAT5 program with…
Keep reading
RIANA Therapeutics 